Hematocrit and drug interference study of the new Arkray Glucocard S Onyx blood glucose meter meeting ISO 15197:2013 accuracy criteria - a contribution to patient safety.

Claudio Burrini¹, Beatrice Morrocchi¹, Nicola Giorgetti², Beate Saeger³

¹Manfredo Fanfani-Lifenet Healthcare group, Laboratory of Clinical Chemistry, Florence, Italy.

²ARKRAY Italia S.R.L, Vimercate, MB, Italy.

³ARKRAY Europe B.V, Scientific Affairs Division, Amstelveen, The Netherlands.

PubMed DOI

Abstract

INTRODUCTION: Abnormal HCT levels and medications can cause inaccurate readings with blood glucose meters (BGM) in routine practice. The GLUCOCARD S onyx (ARKRAY Inc.) BGM was evaluated over a wide HCT range (20-70%) and its interaction with 27 common drug interferences, as per ISO15197:2013/EN ISO15197:2015, compared to clinical laboratory reference methods. METHODS: Pooled venous blood samples…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.